Mycophenolate mofetil (MMF) has proved to be an efficacious and safe therapy in adult lupus nephritis. Recently, this drug has been suggested as a possible new alternative treatment also for juvenile-onset SLE (juvenile-SLE). A multicenter study has been performed to evaluate the efficacy and safety of MMF in controlling the disease activity in children and adolescents with juvenile-SLE. Our results show that MMF was effective in reducing the disease activity or as a steroid-sparing agent in 14 of 26 patients (54%), stabilised the disease in 8 (31%) and was ineffective in 4 (15%). In particular, in patients without renal involvement, a good response was registered in 9 of 13 patients (69%). Among those patients with renal involvement, MMF was effective in 5 of 13 patients (38%), partially effective in 4 (31%) and ineffective in 4 (31%). No severe side effects have been observed; only two patients stopped the drug because of severe diarrhoea and abdominal pain. With the limits of a retrospective study, MMF seems to be effective and safe for the treatment of juvenile-SLE, especially in patients with no renal involvement.
1 Bardsley-Elliot A Noble S Foster RH . Mycophenolate mofetil: a review of its use in the management of solid organ transplantation. BioDrugs1999; 12: 363–410.
2.
2 Eugui EM Almquist S Muller CD Allison AC . Lymphocyte of selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol1991; 33: 161–173.
3.
3 Quiroz Y Herrera-Acosta J Johnson RJ Rodriguez-Iturbe B . Mycophenolate mofetil treatment in conditions different from organ transplantation. Transplant Proc2002; 34: 2523–2526.
4.
4 Chan TM Li FK Tang CS . Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med2000; 343: 1156–1162.
5.
5 Ginzler EM Dooley MA Aranow C . Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med2005; 353: 2219–2228.
6.
6 Pisoni CN Sanchez FJ Karim Y . Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol2005; 32: 1047–1052.
7.
7 Wang J Hu W Xie H . Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus2007; 16: 707–712.
8.
8 Sahin GM Sahin S Kantarci G Ergin H . Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton)2007; 12: 285–288.
9.
9 Contreras G Sosnov J . Role of mycophenolate mofetil in the treatment of lupus nephritis. Clin J Am Soc Nephrol2007; 2: 879–882.
10.
10 Borba EF Guedes LK Christmann RB Figueiredo CP Gonçalves CR Bonfá E . Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int2006; 26: 1078–1083.
11.
11 Buratti S Szer IS Spencer CH Bartosh S Reiff A . Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol2001; 28: 2103–2108.
12.
12 Fu YF Liu GL . Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol2001; 55: 318–321.
13.
13 Carreno L Lopez-longo FJ Gonzalez CM Monteagudo I . Treatment options for juvenile-onset systemic lupus erythematosus. Paediatr Drugs2002; 4: 241–256.
14.
14 Ranchin B . New treatment strategies for proliferative lupus nephritis: keep children in mind. Lupus2007; 20: 1–8.
15.
15 Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
16.
16 Bombardier C Gladman DD Urowitz MB Caron D Chang CH . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
17.
17 Baqi N Moazami S Singh A Ahamad H Balachandra S Tejani A . Lupus nephritis in children: a longitudinal study of prognosis factors and therapy. J Am Soc Nephrol1996; 7: 924–932.
18.
18 Hagelberg S Lee Y Bargman J . Long term follow-up of childhood lupus nephritis. J Rheumatol2002; 29: 2635–2642.
19.
19 Bogdanovic R Nikolic V Pasic S . Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol2004; 19: 36–44.
20.
20 Macdermott EJ Adams A Lehman TJ . Systemic lupus erythematosus in children: current and emerging therapies. Lupus2007; 16: 677–683.
21.
21 Zhu B Chen N Lin Y . Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant2007; 22: 1933–1942.
22.
22 Sahin GM Sahin S Kantarci G Ergin H . Mycophenolate mofetil treatmentfor therapy-resistant glomerulopathies. Nephrol2007; 12: 285–288.
23.
23 Walsh M James M Jayne D Tonelli M Manns BJ Hemmelgarn BR . Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol2007; 2: 968–975.
24.
24 Sixdorf U Bauer H Märker-Hermann E . Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil. Dtsch Med Wochenschr2006; 131: 2266–2269.
25.
25 Pisoni CN Obermoser G Cuadrado MJ . Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol2005; 23: 393–396.
26.
26 Mak A Mok CC . Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus2005; 14: 856–858.
27.
27 Mok CC . Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosous: a systematic review. Scand J Rheumatol2007; 36: 329–337.
28.
28 Szyper-Kravitz M Sheinberg P Sidi Y Schiffenbauer Y Trubniykov E Shoenfeld Y . Hypersensitivity to mycophenolate mofetil in systemic lupus erythematosus: diagnostic measures and successful desensitization. Int Arch Allergy Immunol2005; 138: 334–336.
29.
29 Dasgupta N Gelber AC Racke F Fine DM . Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus2005; 14: 910–913.
